Trial
NCT04918147
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Autoimmunity Centers of Excellence; Bristol-Myers Squibb; Rho Federal Systems Division, Inc.
Condition
IgG4 Related Disease
Intervention
elotuzumab
Why stopped
The study was terminated early based on disease flare/lack of efficacy in the early phase of the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-05